Updated Terms of Use & Privacy Policy

We’ve updated our Terms of Use, and Privacy Policy. Please take a moment to review the changes.

Complete Response to Pembrolizumab as Monotherapy in a Patient with Baseline Stage IV NSCLC with Very High PD-L1 Expression

Pecci ACR graphic

Download (1.62 MB)

General

Complete Response to Pembrolizumab as Monotherapy in a Patient with Baseline Stage IV NSCLC with Very High PD-L1 Expression

Federica Pecci, MD
Italy